Novo Nordisk Fights to Maintain Medicaid Coverage for Weight-Loss Drug Amid State Budget Cuts”
Novo Nordisk is actively working to preserve Medicaid coverage for its obesity drug, Wegovy, as several U.S. states plan to reduce or eliminate reimbursement due to rising costs. The company previously lobbied 14 states to include Wegovy in Medicaid, arguing that the drug could lower long-term healthcare expenses by reducing obesity-related conditions. However, states like…
